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ABSTRACT
The adenosine deaminase enzyme from a Xhosa tribesman 
has been characterized. Red blood cell activity levels 
were 6-9% of normal whereas his white cell ADA levels 
were about 30% of normal. The enzyme's stability at 57°C 
was shown to be greatly reduced suggesting a mutation 
resulting in an enzyme with reduced stability in vivo.
It was concluded that the discrepancy in ADA activity 
levels between red and white blood cells was due to the 
red cells being anucleate.
The proband's residual ADA was found to have a 
Michaelis Constant (K ) for adenosine of 47.9 ♦ IS.BuM,m
a value which is not significantly different from that 
of normal ADA (51.7 ± 11.4ufl).
Red cell deoxy-ATP levels were measured and found 
to be elevated two-to-three times over normal levels.
Red cells from ADA-deficient patients with severe 
combined immunodeficiency (SCID) have been reported 
with deoxy-ATP levels elevated about 1 000 times. It 
was concluded that the slight elevation of deoxy-ATP 
levels in the proband were too low to have any notice­
able effect on functions of his immune system.
Starch gel electrophoresis of red cell ADA from 
members of the proband's family in conjunction with red 
cell ADA activity levels suggested that both parents 
carried a gei e for 'partial' ADA deficiency, both of
which had been inherited by the proband as well as one 
of his sibs. Isoelectric focusing studies suggested 
that the two, parental AUA partial deficiency genes 
were different from one another.
It was also found that another rare allele of ADA, 
possibly ADA ',was segregating within the same family 
although this event appaars to be unconnected with the 
ADA partial deficiency.
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INTRODUCTION
1.1. DISCOVERY OF AODNOSINL DtiAMiNASK DEF1C1HNCY 
As is common with many scientific discoveries, the 
first enzyme deficiency associated with an immuno­
deficiency disease was found serendipitously. In 
the summer of 1972 some blood specimens arrived in 
the laboratory of Eloise Giblett for routine screening 
of genetic markers. The patient was a two year-old 
girl with severe combined immunodeficiency disease 
(SCID). One of the enzymes routinely tested for 
electrophoretic variants was adenosine deaminase 
(E.C.3.5.4.4), which Spencer et al ( 1968) had called 
ADA. To the surprise of Dr Giblott and her staff, ADA 
activity was undetectable in the red cells of the child. 
Her parents had the common ADA-1 electrophoretic 
phenotype but their ADA catalytic activity was 'bout 
half normal. Within weeks blood from a second female 
patient with SCID as well as from her parents was 
tested. This patient's red cells also lacked ADA 
activity and her parents had lower than normal levels. 
Thus it seemed quite possible that, the coexistence of 
these two very rare anomalies was related.
The most likely interpretation of these findings 
was that the parents of both patients were heterozygous 
for the common .1 DA ^ allele and a 1 si lent1 allele at the 
same structural gone locus. The patients had inherited 
the 'si lent' alleles from their parents and, as a conse­
quence, had very little or no ADA catalytic activity.
In the autumn of 197 3 a symposium on SCID was 
held in Albany, New York, and by this time no fewer 
than 12 of 22 patients with SCID had been found to 
be ADA-deficient. The existence cf a causal relation­
ship between the enzyme deficiency and SCID seemed 
highly probable although the mechanism was completely 
obscure.
Shortly before the Albany meeting the first 
example of ADA deficiency without immunodeficiency had 
been described (Jenkins 1973) which if not actually 
casting doubt upon the causal relationship hypothesis 
added another dimension to an increasingly intriguing 
field of research which has increased our understanding 
of the biochemistry of immunodevelopment and indeed our 
appreciation of its complexity.
SEVERE COMBINED IMMUNODEFICIENCY
1.2.1. Description
This syndrome usually presents in infants within 
the first few weeks of life; there are multiple 
infections of fungal, bacterial, viral and protozoal 
origin and these are severe and recurrent. They also 
suffer from diarrhoea and delayed growth and develop­
ment. Candida infections are almost characteristically 
present. If untreated, death occurs within 3 years.
The children are lymphopoenic and show hypoplasia 
and dysplasia of the thymus. Both cell mediated and
antibody mediated immunity are impaired. T cells are 
markedly reduced, most patients with SCID having fewer 
than 5% E-rosetting T cells and often fewer than 2%.
Tests for the capacity of cell-mediated immunity such 
as lymphocyte proliferative responses to antigens and 
mitogens (eg. phytohaemagglutinin(PHA) and to allogeneic 
lymphocytes (mixed lymphocyte response (MLR)) are pro­
foundly depressed. They do not reject skin grafts 
nor do they mount a delayed hypersensitivity skin 
response either to antigens or after sensitization and 
challenge with dinitrochlorobenzene (DNCB). Most 
patients are severely hypogammaglobulinaemic with very 
low levels or even absence of IgG, IgA and IgE. Circu­
lating IgM levels vary from complete absence to normal 
levels. Any circulating immunoglobulins that are found 
are often of maternal origin. Specific antibody responses 
are absent (Gelfand & Dosch 1983) .
Some of the more common clinical and laboratory 
features of SCID are described above. The name 1SCID', 
however, represents a wide spectrum of disorders of 
complex heterogeneity but despite this patients all 
manifest a profound impairment of functional activity in 
T and B cells.
1.2.2. ADA deficiency and SCID
SCID can be inherited in an autosomal recessive 
or X-linked recessive fashion. ADA deficiency has been
found to be associated with one third to one half of 
SCID cases where the mode of inheritance is not 
obviously X-linked. A survey of 130 patients with SCID 
including both autosomal recessive and X-linked modes 
of inheritance (Hirschhorn «6 al 1979; Hirschhorn 1979? 
Ackeret et al 1976) revealed 22% with ADA deficiency.
The clinical presentation of the two cases 
reported by Giblett e t al (1972) was no*-, however, 
exactly as described above. Both patients showed a clear 
impairment of cell mediated and humoral immunity but 
humoral immunity was not as severely affected as cell 
mediated immunity. In fact, some specific antibody 
responses were demonstrated and one patient remained 
healthy until the age of 2 years, older than any other 
child at presentation. Clinical manifestations usually 
develop when the child is aged 3-6 months but it appears 
that 10-15% of SCID cases due to ADA deficiency suffer 
from a less severe, more gradual, but nonetheless, if 
untreated lethal form of the disease. This seems to be 
due to normal or increased numbers of B cells although 
the antibody response reveals qualitative and quanti­
tative abnormalities. Ig levels however, eventually 
fall. The clinical heterogeneity of ADA-deficient SCID 
could be due to genetic heterogeneity or random differ­
ences in exposure to foreign agents.
During the early studies on patients with ADA
deficiency it appeared that two features might dis­
criminate between ADA-deficient and non-ADA-deficienu 
SCID patients. The first of these were bony abnormali­
ties, evident on physical examination, as prominence 
of the costochondral junctions similar to a rachitic 
rosary (Wolfson & Cross 1975; Cederbaum et al 1976). 
Cupping and flaring of the costochondral junctions are 
seen on X-ray examination as is a dysplastic pelvis. 
These changes are not, however, pathognomonic of ADA- 
deficient SCID because similar radiologic changes can 
be observed in non-immunodeficient patients who are 
severely malnourished as well as in ADA-normal immuno- 
dei.icient patients (Hirschhorn, Vawter et al 1 979). 
Despite the fact that these bony abnormalities are not 
specific, they have been clinically useful in alerting 
physicians to the possibility of ADA-deficient SCID.
The second postulated specific feature of ADA-deficient 
SCID was a difference in thymic pathology; ADA- 
deficient patients retained some Hassall corpuscles 
(Huber & Kersey 1975), suggesting secondary atrophy of 
a previously differentiated thymus although subsequent 
studies have failed to find a correlation (Hi.schhorn, 
Vawter et al 1979).
Neurological abnormalities have been reported 
in three cases of ADA-deficient SC'D which seem to 
reflect the interaction of accumulated purines with
6.
purinerqic receptors on bra in cells (Hirschhorn 1979;
Polmar ct a! 1976; Hirschhorn ft at 1983).
1.3. MCTAD0L1C ROLE OF ADA
Adenosine deaminase is a key enzyme in the ourine sal­
vage pathway. It catalyzes the irreversible deamination 
of adenosine and deoxyadenosine by hydrolysis to 
inosine and deoxyinosine respectively, and occurs in all 
tissues where it has been looked for (Van der Weyden & 
Kelley 1976). The specific catalytic activity of ADA is 
highest in normal lymphoid tissues, particularly the 
thymus and spleen (Van der Weyden & Kelley 1976; Carson eta I 
1977; Martin & Ge 1fand 1981). In lymphoid cells the 
activity is higher in the T cells (Barton *it. al 1979) 
than in the B cells.
The processes of A? novo synthesis of purines 
and pyrimidines generate inosine monophosphate and 
uridine monophosphate respectively, which are compounds 
with completed heterocyclic rings (Figs 1-2). The 
presence of the charged phosphates greatly hinders 
their transport across cell membranes. Mammalian tissues 
possess one or both kinds of nucleotidase, intracellular 
(Magnusson 1971; Fritzson 1978) and extracellular (De 
Pierre at a I 1974; Fie it et a I 1975) which remove the 
alpha-ohosphates, thereby generating nucleosides that 
traverse cell membranes both by | isslvo diffusion 
(Plagemann 1L ' 1) and facilitate . transport (Plagemann 
1971; Plagem.v.i n L<.ue 1*V4; Cohen, p r al 1979).
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FIGURE 2 : Biosynthesis of pyrimidine nucleotides 
(Martin 1981).
These heterocyclic compounds are synthesized at con­
siderable energy and substrate expense to the cells 
and it would seem that mammalian cells have evolved 
purine (Fig 3) and pyrimidine metabolite salvage 
mechanisms, both within the same cell in which they 
are produced and from the extracellular environment 
to prevent their loss. Several of these purine and 
pyrimidine degradation products, however, are potenti­
al ly toxic to the cell if salvaged in excessive 
quantities. Mammalian cells, consequently, possess a 
means of detoxifying quantities of these useful but 
potentially harmful purine and pyrimidine metabolites.
The cells maintain a proper balance betw< »n the pro­
duction of dephosphorylated purine and pyrimidine 
metabolities, their detoxification by further degra­
dation (Fig 4), and their salvage by metabolism back to 
the nucleotide level (Fig 5). The maintenance of the 
right balance of these processes is crucial to the well­
being of the cells (Fig 6).
The de novo synthesis of purine nucleotides is 
controlled by feedback inhibition at several sites (Fig 1).
Firstly, feedback inhibition of 5-phosphoribosy1- 
1-pyrophosphate synthetase by the purine nucleotides AMP, 
GMP and IMP regulates the level of 5-phosphoribosyl-1 - 
pyrophosphate (PRPP). The committed step in purine 
nucleotide biosynthesis is the conversion of PRPP into 
p h o s p h o r ibosylamine by transfer of the side-chain amino
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reductase; 2, adenyl cyclase; 3, adenylate cyclase,
4, ribosephosphate pyrophosphoklnase; B, methyl trans­
ferase (various enzymes); 6, glytamlne phosphoribosyl 
pyrophosphate amidotransferase.
group of glutamine. PRPP glutamyl aminotransferase is 
feedback inhibited by many purine ribonucleotides.
Inosinate ( MP) is the branching point in the 
synthesis of AMP and GMP. The reactions leading away 
from inosinate are sites of feedback inhibition.
finally, GTP is a substrate in the synthesis of 
AMP, whereas ATP is a substrate in the synthesis of 
GMP. This reciprocal substrate relation tends to balance 
the synthesis of guanine and adanine ribonucleotides.
Deficiency of hypox" -guanine phosphoribo-
syl transferase (HGPRT) is b o t ' error of metabolism
resulting in the Lesch-Nyhan syndrcree. Those affected 
with this disease have a tendency to self -mutilate as 
well as being aggressive towards others. The disease is 
inherited as a sex-linked recessive. The biochemical 
consequences of the virtual absence of HGPRT are an 
overproduction of urate and an elevated concentration 
of PRPP. Also, there is a marked increase in the rate 
of purine biosynthesis by the de novo pathway.
From observations on these patients it is apparent 
that most of the hypoxanthine and guanine produced by 
purine nucleoside phosphorylation, are normally salvaged 
by phosphoribosy1ation via HGPRT, a PRPP consuming re­
action. While H G P R T - d e f icient Lesch-Nyhan patients with 
purine n u c l e o s i d e  phosphorylase deficiency cannot sal­
vage hypoxanthine and guanine due to a deficiency of
15.
these substrates for the salvage reaction. Accordingly, 
both Lesch-Nyhan patients and purine nucleoside phos- 
phorylase deficient patients 'spare- P R P P ,  which In 
turn drives the dr novo purine biosynthesis pathway to 
overproduction. The latter seems to account for the 
massive total purine overproduction In the oat-ents with 
purine nucleoside phosphorylase deficiency and those 
with Lesch-Nyhan.
Adenosine or 2 1-deoxyadenosine may be generated 
within the cell or they may enter the cell by one of 
several facilitated diffusion transport mechanisms (Fox & 
Kelley 1978, Fig 7). Adenosine and 2'-deoxyadenosine can 
be torrned by the dephosphorylation of AMP or 2' -deoxy-ATp 
respectively. Ecto r>'-nucleotidase possess 51-phospho- 
monoesterase activity and is localized in the external 
surface of the plasma membrane of lymphocytes (Webster et 
1 1974»* De Pierre & Karnovksy 1974) . This enzyme is
important in allowing the uptake of adenosine from the 
extracellular AMP pool in human lymphocytes. Intracellu­
lar 5 1-AMP is degraded to adenosine by a specific endo 5'- 
nucleotidase (E.C. i. 1 . 1.3.5) or by non-specific phospha­
tases. The K|n of ecto 5'-nucleotidase has been reported 
as 8.9uM for AMP substrate (Webster r / <i I 1979), and 67|iM 
for endo 5'-nucleotidase (Fox & Kelley 1978) whereas the 
K|n of alkaline phosohatas0 , a non-specific phosphatase 
is 4U0|jM for AMP (Fox & Kelley 1978) although of course, 
there are factors other than Km which determine whether
16.
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FIGURE 7 : Metabolism of adenosine - its formation
and degradation within cells (Fox & Kelley 
1978). (1, S-adenosylmethionine methyltrans-
ferasef ; 2. S-adenosylhomocyteine hydrolase; 
3, adenosine deaminase; 4, purine nucleoside 
phosphorylase; 5 & 6, xanthine oxidase; 7, 
transport mechanisms; 8, adenosine phosphory­
lase (not establsihed); 9, adenosine kinase; 
10, 5'-nucleotidase and non.specific phospha­
tase; 11, adenylate kinase; 12, nucleoside 
diphosphokinase; 13, adenylate cyclase.
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one enzyme or another plays the more significant rdle 
in dephosphorylating AMP.
The in vivo site of generation of adenosine and 
deoxyadenosine is not known. Chan (1979) described an 
experimental model system studying purine excretion by 
macrophages using mouse peritoneal macrophages. Normally, 
macrophages excrete a large quantity of uric acid into 
the culture medium. However, in the presence of deoxyco- 
formycin, a potent inhibitor of ADA, these macrophages 
also excreted deoxyadenosine. Furthermore, phagocytosis 
f nucleated erythrocytes augmented the excretion of 
deoxyadenosine. Macrophages are involved in the phago­
cytosis of nuclei that are extracted from normoblasts 
during erythrophoiesis and also of senescent cells in 
lymphoid organs. Chan proposed that macrophages of the 
reticuloendothelial system are a source of deoxyadenosine.
Another potential source of intracellular adenosine 
is the degradation of S-adenosylhomocysteine to adenosine 
and homocysteine (Fig 8 ). This hydrolysis reaction is 
catalyzed by the enzyme S-adenosylhomocysteine hydroleue 
(SAHH, E.C. 3.3. 1.1) which in humans has its highest 
activity in liver, pancreas and kidney (Fox & Kelley 1978). 
The equilibrium of the reaction strongly favours form­
ation of S-adenosylhomocysteine. The in vivo reaction 
favours degradation since the breakdown products, adeno­
sine and homocysteine, are more easily removed by further 
degradation than S-adenosylhomocystelne (De la Haba &
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Canton! 1959) . The of the enzyme is 1.5mM for adeno­
sine and 4.BmM for L-homocysteine and these compounds 
inhivit the hydrolytic reaction (Walker & Duerre 1975). 
Since the equilibrium favours S-adenosylhomocysteine 
formation, the reaction acts as a sink for adenosine 
when it has not been hydrolysed by ADA (De la Haba & 
Cantoni 1959). The removal of S-adenosylhomocysteine is, 
however, an Important metabolic event, because this com­
pound Is a strong competitive Inhibitor of all trans­
methylation reactions mediated by S-adenosylmethionine 
(Zappla et al 1969; Pegg 1971; Kerr 1972; Click et al 
1975). Adenosine and deoxyadenosine may be removed from 
cells by direct release to the extracellular environment, 
by synthesis to adenine nucleotides or by degradation to 
purine end-products. The mechanism of direct release of 
adenosine appears to be particularly important in the 
liver suggesting that the liver acts as a potential source 
of purine substrate to other tissues (Lerner & Lowy 1974; 
Pritchard *t jl 1975). The mechanism of release is not
known.
The degradation of adenosine and deoxyadenoslne 
begins with their deamination by ADA to inoslne and deoxy­
adenoslne, respectively. Although the deamination of 
adenosine and deoxyadenoslne is probably a neceosary 
detoxification process, It 1= In humans a quantitatively 
minor contributor to the overall degradation of purines 
to the usual excreted form, uric acid. Those patients
with adenosine deaminase deficiency have normal levels 
of plasma and urinary urate (Mills et al 1978; Simmonds 
dt al 1978).
The Kni of ADA in lymphocytes, fibroblasts and 
erythrocytes for adenosine and deoxyadenosine is about 
40tiM to 70uM for both (Dadonna & Kelley 1979; Hirschhorn 
e t al 1976) . The differences in the level of enzyme 
activity in various tissues appears to be related to 
the molecular form of the enzyme that predominates.
There appear to be two soluble molecular forms of ADA 
with molecular weights of approximately 36 000 and 298 000 
(Van der Weyden & Kelley 1976). These two forms are inter­
convertible in the presence of a protein that has an 
apparent molecular weight of 200 000 and has no adenosine 
deaminase activity (Van der Weyden & Kelley 1976). The 
small form of the enzyme predominates in tissue prepa­
rations exhibiting the higher specific enzyme activities 
such as spleen and stomach and which have no conversion 
activity whereas the large form of ADA predominates in 
tissue extracts exhibiting the lower enzyme activities 
and plentiful conversion activity such as kidney and lungs 
(Van der Weyden & Kelley 1976). An optimal level of ADA 
activity is essential for normal cell function in man 
since a deficiency of the enzyme is associated with an 
increased Intracellular concentration of adenine mucleo- 
tides (Agarwal al 1976; Polmar et al 1976) and an 
increased level of activity with the opposite effect
(Valentine et a I 1977).
The removal of adenosine and 2 1-deoxyadenosine Ly 
their conversion to nucleoside monophosphates is cata­
lyzed by adenosine kinase (Fig 9) or, more importantly 
for deoxyadenoMine, deoxycytidine kinase. Adenosine 
kinase occurs in all tissues but has it's highest activity 
in liver, spleen and lymph nodes (Krenitsky st al 1974).
The K value of adenosine kinase for adenosine
m
(0 .4-6 .OuM) is significantly lower, by an order of magni­
tude, than that of ADA for adenosine whereas for deoxy­
adenosine the K of ADA is an order of magnitude lower
m
than either adenosine kinase (400-1800uM) or deoxycytidine 
kinase (330-400uM) (Fox & Kelley 1978; Martin & Gelfand 
1981; Ochs et al 1979; Carson & Kaye 1979).
When adenosine enters the cells, several factors 
determine whether it is to be converted to nucleotides or 
inosine. The utilization of adenosine is dependent upon 
the relative activities of ADA and adenosine kinase. At 
low concentrations adenosine is preferentially phosphory- 
lated to AMP, but at concentrations above 3yM, degradation 
of adenosine to inosine and hypoxanthine is favoured 
(Schrader et al 1972). D e o x y a d e n o s i n e  will be preferenti­
ally deaminated by ADA at normal intracellular concen­
trations with phosphorylation occurring only at high 
concentrations, whether it be by adenosine kinase or 
deoxycytidine kinase (Carson „  1979, Carson . Kaye 
1979; Ullman et <*£1981).
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Adenosine and deoxyadenoslne metabolism may be 
altered during cell proliferation. Adenosine deaminase 
activity increases in regenerating mouse liver (Rothman 
a I 1971). Transformation of monocytes to macrophages 
is accompanied by a two-to-ninefold increase in the 
levels of ADA activity (Fischer et al 1976) . Adenosine 
deaminase activity increases up to fourfold in phytohaemag- 
glutinin-stimulated lymphocytes at 24-60 hours (Hovi et 
al 1976) and decreases to 44% of values at 72 hours 
(Snyder et al 1976) while adenosine kinase does not change
(Snyder et al 1976). In stimulated or unstimulated lympho­
cytes, phosphorylation orcurs when adenosine is present 
at a concentration below SuM or 0.5uM, respectively. It 
seems possible that there Is either an Increased formation 
of adenosine or an Increased entry o f adenosine Into these 
stimulated lymphocytes. Nucleoside transoort rates have. 
Indeed, been found to Increase during cell proliferation 
(Berlin « Olivier 1975). Inhibition of ADA with or with­
out the addition of adenosine or deoxyadenoslne prevents 
the proliferation of monocytes and lymphocytes (Snyder «t 
al1976, Carson «t al1977, Fischer 1976, Hovi 
at al 1976, Carson 4 Seegmlller 1976; lor ' t al 1975,
Oilman st al 1976). Thus adenosine metabolism, modulated
by ADA activity may be important during cell proliferation.
PIIRTNK NUCLEOSIDE PHOSPHORVLASE (PNjl
Purine nucleoside phosphorylase catalyses the conversion
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ot inosine and deoxy1 nonino, the products of ADA, to 
hypoxanthi.no and rihose 1-phosphate and dooxyribooe- 
1-phosphate. The structural qeno for ourine nucleoside 
phosohorylase in humans has been assigned to the ql 3 
band of chromosome 14 and codes for a 38 000 molecular 
weight subunit that combines with two other identical 
subunits to form the trimerIc holoenzyme. This enzyme 
occurs throughout all human tissues but the peripheral 
blood lymphocytes, granulocytes and erythrocytes and 
the kidney contain the highest specific catalytic 
activities. Absence of this enzyme is associated with 
an immunodeficiency syndrome which is distinct from ADA- 
deficient associated SCID (Martin & Gelfand 1980).
Features of PNP-deficient immunodeficiency are 
severely depressed T cell functions as assayed by the 
response of lymphocytes to mitogens and allogeneic cells 
and mirked reduction in T cell numbers. B cell immunity 
is normal or enhanced as evidenced by normal to elevated 
immunoglobulin levels, normal antibody response to anti­
gens (even when T cell immunity is absent), normal num­
bers of B cells in the peripheral blood and normal numbers 
of plasma cells in lymphoid tissue. Biochemically the 
disorder is characterized as having normal to elevated 
adenosine deaminase levels, less than 1% of normal purine 
nucleoside phosphoryInse activity, reduced serum uric 
acid levels. Increased plasma levels of Inosine, deoxy-
inosine, guanoaine and ieoxyguanosine, increased intra­
cellular concentrations of Jeoxy-GTP and increased 
urinaiy excretion of inosine, guanosine, deoxyinosine 
and deoxyguanosine (Martin & Gelfand 1980).
In both ADA and PNP deficiency the primary target 
for metabolic damage appears to be the T cell, although 
ADA-deficient patients also develop B cell dysfunction 
at some stage of their immunodeficiency disease. The 
fact that B cell function is normal or nearly normal in 
PNP deficiency is likely to reflect a difference in the 
metabolic pathways between the two cell types. The 
nearly complete containment of cellular dysfunction to 
lymphoid cells in both diseases indicates the dependence 
of these cells on part of the purine salvage pathway not 
apparently necessary in other cells of the body (Martin & 
Celfand 1980).
MECHANISMS RELATING ADA DEFICIENCY TO SCID
1.5.1. Adenosine-Induced pyrimidine starvation (Figs 1 & 2)
This theory was based on the finding that abnormal 
concentrations of adenosine caused elevated levels of 
purine nucleo ies and reduced levels of pyrimidine nucleo­
tides (Green & Chan 1973). ^he growth rate of a cultured 
lymphoblastoid cell line established from blood cells of 
a patient with infectious mononucleosis was affected In 
this way when incubated with adenosine at concentrat ions 
higher than 1wM. This effect was prevented when uridine 
was provided as a source of extra pyrimidines indicating
that the adenosine Induced toxicity was mediated by 
the lack of pyrimidines.
The addition of adenosine to cultured mammalian 
cells, also leads to an accumulation of orotic acid 
which appears to be due to a reduction in the activity 
of orotate phosphoribosyltransferase (OPRT) the enzyme 
that catalyzes the conversion of orotic acid to orotidine 
5'-monophosphate (Green & Chan 1973; Fox & Kelley 1978).
Adenosine is capable of trapping by phosphory­
lation to its nucleotides. Under physiological conditions 
the decrease of intracellular concentration is accom­
panied by the inhibition of phosDhoribosyloyrophosphate 
(PRPP) formation. Thus the accumulation of orotic acid 
might be explained by the ability of adenosine to limit 
the jntracellular concentration of PRPP, a substrate for 
OPRT (Planet & Fox 1976). However, evidence that an 
adenosine kinase-deficient cell line was as sensitive to 
adenosine as the adenosine kinase-positive cell line 
suggested tha t  adenosine does not need to be converted to 
its nucleotide in order to cause pyrimidine starvation 
(Hersl.field e t at 1977; Snyder 9t at 1 977). There are 
several lines of experimental evidence which undermine 
the importance of a d e n o s i n e - i n d u c a d  pyrimidine starvation 
leading to immune dysfunction.
i. Adenosine levels in plasma of ADA-deficient SCID
patients were found to be Insufficient to induce pyrimi­
dine starvation (Cohen et at 1978; Green & Chan 197 3;
Mills et at 1976).
ii. Pyrimidine nucleotides UTP, CTP, deoxy-TTP and 
deoxy-CTP were found to be elevated in an ADA-deficient 
SCID patient although this may be ascribed to erythrocyte 
transfusions given to this child (Hutton et al 1981; 
Schmalstieg et al 1977).
iii. ADA-deficient- .1 dr an do not excrete elevated
amounts of orotic acid (Mills et al 1979).
iv. Despite onstrable adenosine and deoxyadenosine 
mediated alterations of pyrimidine metabolism, these 
changes are not accompanied by marked interference of 
cell growth for ADA-deficient lympi •'bla ts (Parker et al
1982).
1.5.2. PRPP starvation (jee I* igs 1,2,3 & 6 )
PRP P  concentration is reduced in human lymphoblasts 
in the presence or adenosine due to inorganic phosphate 
being utilized to make phosphorylated adenosine derivatives. 
PRPP is an essential substrate not only for the de novo 
synthesis of pyrimidine but also for de novo purine bio­
synthesis, ourine salvage pathways and pyrimidine nucleo­
tide synthesis. It is possible that inhibition of pyrimi­
dine synthesis as described above, is secondary to a 
decrease in the cellular concentration of PRPP. This is 
due to a decrease in the synthesis of PRPP when inorganic 
phosphate is limiting. A decrease in the intracellular
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concentrations of this compound could therefore have 
profound metabolic effects. Further studies are required 
to determine the importance of PRPP mediated toxic effects 
on the immune system (Fox & Kelley 1978; Planet & Fox 
1976; Snyder <? t al 1976).
1.5.2. Inhibitio?& of S-adenosyIhomocysteine hydrolase
by adenosine and deoxyadenosine (Figs 8 & 10)
S-adenosyIhomocysteine hydrolase (SAHH) catalyzes 
the reversible hydrolysis of S-adenosyIhomocysteine to 
adenosine and homocysteine (D e  la Haba & Cantoni 1 9 5 9 ) .  
Physiological conditions favour this reaction although, 
kinetically speaking, the equilibrium position strongly 
favours the reverse reaction, because SAHH has a high 
binding affinity for adenosine. It was found that lympho­
blast cell lines incubated with an ADA inhibitor such as 
deoxycoformycin (dCF) and adenosine show a striking ele­
vation of S-adenosyIhomocysteine (Kredich & Hershfield 
1979). Deoxyadenosine does not act as a substrate for 
SAHH, but it binds to the enzyme irreversibly in such a 
way as to make the active site of the enzyme inaccessible 
resulting in a "suicide" inactivation of SAHH. S-adeno­
sy Ihomocysteine then accumulates from both directions, 
as seen In FI,jure 8 (Hershfield 1979, Hershfield « 
Kredich 1979; H e r s h f i e l d  et „/ 1974). The hypothesis 
suggests that the accumulated s-adenosylhomocystelne 
Inhibits the trans-methylatIon reactions of S-adenosyl- 
methionine (S A M ) many of which are physiologically
29.
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important . Another important result of the cleavage 
of S-adenosyIhomocysteine by SAHH is the release of 
homocysteine. This reaction is the only source of ho- 
mocysteine which is used in the synthesis of the essen­
tial amino acid methionine in a reaction that also 
produces tetrahydrofolate, a co-factor for several enzymes 
participating in the synthesis of nucleic acid precursors.
It is known that adenosine and deoxyadenosine 
accumulate in the lymphocytes of ADA-deficient patients 
and so the accumulation of S-adenosyIhomocysteine could 
occur by the action of either of the two ADA substrates.
It has been postulated that these toxic effects are not 
manifested until the lymphocytes are stimulated to divide. 
The cell is in a poor equilibrium position for methylation 
reactions as the concentration of S-adenosyIhomocysteine 
is high, removal of it is blocked by the ADA deficiency 
causing an accumulation of adenosine favouring the 
reverse reaction and the accumulated deoxyadenosine is 
inhibiting the SAHH. The result of the extra burden of 
the immunostimulus is that things go from bad to worse 
and the cell "commits suicide" (Kredich 1^74). Lympho­
cytes are long-lived cells which synthesise relatively 
small amounts of protein, so time allows the accumulation 
of S-adenosyIhomocysteine whilst the low levels of pro­
tein production in the resting state do not impose too 
much stress on the impaired metabolism of the cells. 
ADA-deficient SCID patients have been reported to lack
SAHH activity in their erythrocytes due to in vivo 
inactivation by deoxyadenosine (Hershfield 1 9 7 9 ; Hersn- 
field ct a 19/9). Data against this hypothesis includes 
experiments in human T and B lymphoblast; and in peri­
pheral blood lymphocytes showing that no correlation 
could be found between inhibition of SAHH by deoxyadeno­
sine and deoxyadenosine induced lymphocytotoxicity 
(Keffovd et at 19821 .
Interestingly, it has been shown that ADA and
5 iHH are s venic on chromosome 20. This is a small 
chromosome containing only 2.4% of the total haploid 
autosomal length and so the chances of any one locus 
occurring in chromosome 20 is approximately one in forty. 
The occurrence of two functionally related loci together 
on this chromosome suggests the necessity for further 
enquiry rather than simply putting it down to chance 
(Hershfield & Francke 1982).
1.5.4. Inhibition of ribonucleotide reductase by 
deoxy-ATP (Fig 11)
Ribonucleotide reductase catalyzes the conversion
of ribonucleotides at the diohosphate level to deoxy- 
ribonucleotides. This is the only route known for 
synthesis of deoxyribonucleotides in mammalian cells and 
so would appear to be essenti ■ i ■ for DNA synt hesis (Moore
6 Hurlbert 1966; Reichard 1972). Using highly purified 
calf thymus ribonucleotide diphosphate, it was shown
nboniK ieolieie 
redut I ds»*
A DP —  
GDP —  
COP —  
UDP —
deo*y ATP •**
t
t
t
deo*y»denoini#
* deoNy a  DP  
d ro ny  G D P  
- ( Irony C D P  
- »  d ro n y  U D P
drony ATP
drony GTP 
dronv CTP 
drony T TP
ADA
- ♦  dronym osinr
PNP
hyponanihinr
nanlhinr
uric acid
drony GTP
t
t
I
dronygjanosinr
dro.nyriboie
Vpiiosphate
J - PNP
goaninr
FIGURE 11 : Inhibition of ribonucleotide
reductase by deoxy-ATP and deoxy-GTP 
in ADA and PNP deficiency.
that deoxy-ATP at a concentration of 5uM inhibits 50% of 
the ADP, GDP, GDP and UDP reactions (Eriksson et al'
1979). In ADA deficiency there accumulates deoxyadeno— 
sino, which can be phosphorylated to the deoxyribonucleo- 
tides, deoxy-AMP, which subsequently increases the 
intracellular level of deoxy-ATP. Elevated deoxy-ATP 
levels have been found in cells of immunodeficient 
patients. Inhibition of ribonucleotide reductase by 
deoxy-ATP could cause an imbalance of the intracellular 
deoxyribonucleotide pools and thus impair DNA synthesis.
The phosphorylating capacity of thymus, spleen 
and peripheral lymphocytes is high when compared wit: 
other tissues (Carson et xl 1977). In experiments with 
cultured cell lines of human B and T lymphoblasts it was 
Ljen that, when culturing both cell lines with deoxy- 
adenosine, cell growth was more markedly inhibited in the 
T cell line than in the P cell line (Mitchell et al 1978). 
Together with this selective toxicity a selective accumu­
lation of deoxy-ATP in the T lymphoblasts was observed 
(MitcheU . t al 1978). This difference was shown to be 
not due to different rates of phosphorylation of deoxy- 
adenosine since both cell types had a similar enzymatic 
capacity for catalyzing this reaction. Marked differences 
in the nuclootide degrading capacity, however, were 
noticed. 5'-purino nucleotidase (5'NT), the enzyme de- 
phosphorylating deoxy-AMP and other mononucleotides to 
give the corresponding nucleosides, was found to have
much lower activity In T than in B coll. (T h o m p s o n  . t „l 
1979; van Laarhoven anj 1e Bruyn 1,83, Wortmann 
.!f ai 1'l79). Thus, the more rapid accumulation of deoxy- 
A1P mUjht be considered to be the net result of both 
kinase and nucleotidase activity.
This mechanism is currently Lhe most popular and 
t* Is now widely believed that deoxy-ATP inhibition of 
ribonucleotide reductase forms the biochemical basis of 
immunodeficiency in ADA-deficient SCID. This hypothesis 
lias, however, been criticised on a number of scores.
There are u ubts about the selective toxicity towards T 
and D colls b ing explained on the basis of differences 
in activity of 5 '-NT ,an enzyme which has a considerable 
part of its catalytic activity located at the outer 
surface of the cell membrane (van Laarhoven & de Bruyn
1983).
Recent evidence suggests that the two mechanisms, 
inhibition of SA11H by dcoxyadonosine and adenosine and 
inhibition of ribonucleotide reductase by deoxy-ATP may 
have differing degrees of importance in the production 
of toxicity in resting lymphocytes and urolIterating 
lymphocytes (Lee > ? i! 1982). In acute T cell leukaemia 
the lymphocytes are resting ie. there is little DNA synthe 
sis. Treatment of this condition with deoxycoformycin 
(dCF), a powerful inhibitor of ADA, has often been found 
to bring about a state of complete remission (Prentice
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et a I V)80, 1 981 ; Grever c t a I 1981). Deoxycoformycln 
treatment brings about a state similar to that in ADA- 
deticient SC ID patients in terms of elevated metabolites. 
In acute T cell lymphocyte leukaemia, remission implies 
that the T cells have been destroyed. In this situation 
where the T cells are resting it is unlikely that 
inhibition of ribonucleotide reductase is going to be a 
major factor in their death. In resting lymphocytes 
treatment with hydroxyurea, an inhibitor of ribonucleotide 
reductase, failed to produce toxicity. Decreased SAHH 
activity was also seen, however, suggesting that in 
resting lymphocytes toxicity was mediated through inhi­
bition of that enzyme or even by ATP depletion which is 
necessary for numerous metabolic reactions (Lee et alt
1984) .
In proliferating lymphocytes inhibition of ribo­
nucleotide reductase is now the mechanism of choice for 
explaining the immune dysfunction. Deoxy-ATP concen­
trations are always highly elevated whilst SAHH activity 
is insignificantly altered. In fact, a B cell line 
despite almost complete inhibition of SAHH when rapidly 
proliferating, showed little toxic effects.
1.5.5. Adenosine Induced elevation of intracellular
c y c l i c  AMP
The Intracellular concentration of cyclic AMP is 
increased by adenosine in many tissues, including lympho­
cytes. Elevated levels of cyclic AMP may occur as a
direct tesult ot t he metabolic transformation of adeno­
sine to cyclic AMI’ although a more important mechanism 
relates to the activation of plasma membrane adenylate 
cyclase by adenosine (Fox & Kelley 1978). As a result 
of elevated adenosine and deoxyadenosine levels in ADA 
deficiency, intracellular cyclic AMP levels in cells of 
the lymphoid system may be increased by either of the 
above mechanisms.
It is known that phytoha i',glutinin induced 
human lymphocyte blastogenesi s inhibited by cyclic 
AMP. Excretion of antibodies and lymphocyte mediated 
toxicity are also affected by this compound.
Whether the derivation of intracellular cyclic AMP 
plays an important role in the biochemical mechanisms 
leading to immune dysfunction in ADA deficiency is not 
yet clear. ADA-deficient leukocytes contained a cyclic 
AMP concentration <5mols/10fi cells) about twice as high 
as control leukocytes (2.6mols/106 cells) (Schmalstieg 
ct ai 1977) , however, the inhibitory effects of cyclic 
AMP described above were seen only at concentrations over 
IOOuM. In addition T cell lymphosarcoma cell lines which 
•fioxo defective in some components of cyclic AMP action 
or metabolism, were resistant to increased cyclic AMP 
levels but sensitive to killing by adenosine and erythro- 
9 - (2-hydroxy 3-nonyl) adenine (EHNA) (Oilman et al 1976).
Those findings c»i t doubt on th#' importance of this 
mechanism in mediating the toxic effects of ADA 
dev icjency.
BIOCHEMICAL BASIS OF THE IMMUNE DYSFUNCTION IN
LYMPHOCYTES
Any hypothesis which tries to explain the association 
of ADA deficiency and immune dysfunction in terms of 
biochemical mechanisms must also take into account 
the preferential impairment of lymphocyte - particu­
larly T lymphocyte - growth and development. Adenosine 
deaminase deficient children with immunodeficiency 
accumulate abnormally high concentrations of adenosine 
and deoxyadenosine in their plasma and urine but excrete 
normal quantities of total purines because, as ex­
plained above, adenosine and deoxyadenosine, in absolute 
quantitative terms, are a relatively minor component of 
the total purines excreted (Van der Weyden & Kelley 
1976; Simmonds et al 1978; Mills et al 1978; Donofrio 
et al 1978; Mills et al 1976). The erythrocytes, 
lymphocytes and bone marrow jells from ADA-deficient 
patients exhibit markedly elevated concentrations of 
deoxy-ATP (Donofrio et al 1978; Cohen et a! 1978; 
Coleman et a I 1978; Chen et al 1978; Cohen, Gudas et 
al 1978) and deoxy-ADP (Coleman et al 1978; Chen et al
1978) .
Observations on lymphoblast cell lines suggest 
that human T - l y m p h o b l a s t s  are far more susceptible to
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deoxyadonosine toxicity than arc B lymphoblasts and 
this susceptibility correlates with an Increased 
ability of T  cells to accumulate deoxy-ATP. "" lympho­
blast cell lines accumulate deoxy-ATP and are killed 
when cultured in the presence of deoxyadenosine during 
ADA inhibition whereas B lymphoblasts are resistant and 
do not accumulate deoxy-ADP (Mitchell et al 1978). 
Studies have shown that ADA inhibited T lymphoblasts 
accumulate deoxy-ATP at a rate of 20 to 45-fold faster 
than B lymphoblasts (Wortmann 1979).
The faster rate of accumulation in T cells of 
deoxy-ATP than B cells could be due either to an 
increased rate of phosphorylation of deoxyadenos ine in 
T cells to form deoxyribonucleotide or a faster rate 
of dephosphorylation in B cells from the deoxyri» onu- 
cleotide to the deoxyribonucleuside. It has been 
proposed that selective phosphorylation and trapping 
by T  lymphocytes of deoxyadenos.ine mediated by lympho- 
specific deoxyribonucleoside kinase leads to an accumu­
lation of toxic deoxyribonucleotides (Carson et al
1978). Human T lymphoblast cell lines were founa to 
be more sensitive than human B cell linos to the growth 
inhibitory effects of deoxyadenosine. This differential 
sensitivity cound not be attributed solely to the 
relative amounts of deoxyadenosine phosphorylating 
activity b u t  did correlate with the ability of the 
c e l l s  to a c c u m u l a t e  d e o x y - A T P .  Therefore it seemed
possible that. T and B cell lines might differ In their 
rate of deoxyribonucleotide breakdown (Carson et al
1979).
Deoxyadenosine phosphorylation can occur through 
adenosine kinase or deoxycytidine kinase for both of 
which, however, It is a poor substrate. At low but 
potentially significant deoxyadenocine concentrations, 
deoxycytidine kinase is the major route of phosphory­
lation. Deoxycytidine kinase is a lyirphospecific enzyme. 
At higher deoxyadenosine concentrations, adenosine 
kinase, which occurs ubiquitously assumes the more 
important role in human ly: pnocytes (Carson et al 1977). 
Overall, phosphorylating activity of deoxyadenosine is 
only slightly higher in T cells than B cello and cer­
tainly not high enough to explain the discrepancy in 
deoxyribonucleotide levels (Carson et al 1981; Carson 
*’t al 1979; Wortmann 1979) .
T cells have been demonstrated to breakdown 
deoxyribonucleotides far more slowly than B cells which 
is in accordance with the observation that T cells have 
much lower 5'-nucleotidase activity than B cells. 
Therefore, the combination of high deoxyribonucleoside 
phosphorylating activity and low deoxyribonucleotide 
dcphosphorylating activity makes T lymphoblast cell 
lines inordinately susceptible to the toxic effects of 
deoxyribonucleosides and their analogues (Carson et al
1979). Enzyme activities in T cell lines are high for
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ADA and dooxycytidlne kinase and adenosine kinase and 
low for 5'-nucleotidase compared with B cells. In the 
absence of ADA, T cells accumulate phosohorylated 
derivatives of deoxvadenosine itore rapidly than B 
cells a 1onq with the associated toxic effects. Studies 
of 5 '-nucleotidase activity revealed that the membrane 
bound ecto-5'-nucleotidase activity levels were not 
related to the degree of deoxyadenosine toxicity. Rather, 
a soluble deoxyrucleotidase activity occurring in T and B 
lymphoblastoid cell lines was inversely related to deoxy­
adenosine toxicity in ADA-inhibited cell lines. This 
soluble nucleotidase had different characteristics from 
the ecto-5'-nucleotidase (Carson et al 1981; Fritzson 
1977).
ADENOSINE DEAMINASE (ADA)
1.7.1. Molecular heterogeneity and ADA binding protein
Studies of ADA from a variety of human tissues 
have provided evidence for molecular heterogeneity. In 
some tissues ADA exists exclusively as the small molecular 
form (molecular weight 33 000-33 000) while in other 
tissues the large .olecular form of the enzyme predomi­
nates (molecular weight 220 000-298 000) * adonna & KeiLp v
1979). It has been shown that under mildly denaturing 
conditions (50mM sodium succinate or 2.7M guanine hydro­
chloride) the large form of ADA can be converted to the 
small form of the enzyme (Akedo et al 1971; Van der
Weyden & Kelley 1976) and, conversely, that in the 
presence of appropriate tissue extracts, such as kidney, 
the small form of ADA can be converted to the large form 
of the enzyme. The interconvorsion is due to the enzyme 
molecule associating with a specific ADA binding protein 
(Van der Weyden & Kelley 1976; Nishara et al 1973; 
Hirschhorn 1975). Conversion of the small form to the 
large form of ADA occurs at 4°C, exhibits a pH optimum 
of 5.0 to 8.0, is associated with loss of binding protein 
activity of the cell extract and cannot be mimicked in 
vitro by other proteins, changes in ionic strength or by 
pH effects (Van der Weyden & Kelley 1976). Adenosine 
deaminase binding protein has been purified from human 
kidney which is the tissue with the highest binding pro­
tein activity. Analyses by SDS polyacrylamide qel elec­
trophoresis and with Schiff staining suggest that the 
binding protein has a molecular weight of about 200 000 
and that it is a dimeric glycoprotein consisting of two 
identical subunits each with a molecular weight of about 
100 000 (Dadonna & Kelley 1977). Stoichiometric analysis 
suggests that the binding protein associates with ADA in 
the molecular ratio of 1 to 2 (Dadonna & Kelley 1 977). 
This association is responsible for the appearance of 
the large form of ADA seen in lung and kidney tissue and 
skin fibroblasts. The association is reversible, hence 
the i n t e r c o n v e r t i b i l i t y  of the large and small s-ecies. 
The binding protein is located on the internal and
external cell surface attached to the cell membrane where 
it appeals to act as an anchor for the ADA enzyme. The 
soluble cytoplasmic form of the binding protei-. appears 
to be generated during tissue disruption by proteolysis 
of the membrane form (Andy & Kornfeld 1982, 1984).
The function of the catalytically inactive ADA 
binding protein remains elusive. The large form of ADA 
appears to have increased heat stability suggesting that 
the binding protein may stabilize ADA in vivo. The 
specific activity of the large form, in addition, appears 
to be lower than the small form. Tissues with low 
ADA activity contain predominantly the large form of ADA 
and have high levels of binding protein.
The genetics of the ADA binding protein is 
interesting in that at least two loci, on chromosomes
2 and 6, are required for its expression (Koch & Shows 
1978; Herbschleb-Voogt at al 1978), and it has been 
suggested that additional genes may be involved in the 
control and processing of ADA tissue isozymes (Koch & 
Shows 1978).
The small form of ADA has been purified from human 
erythrocytes, which are a readily available source of the 
enzyme (Dadonna & Kelley 1979: Dadonna & Kelley 1977;
Schrader et aL 1976; Osborne et al 1973). Purified 
erythrocyte ADA analysed by native polyacrylamide gel 
electrophoresis revealed three bands by Coomassie stain, 
each of which had ADA activity. Sodium dodecyl sulphate
(S D S )  polyacrylamide gel electrophoresis of this prepa­
ration revealed only the major band of protein by 
Coomassie stain suggesting that the native enzyme existed 
as charge isomers rather than size isomers (Dadonna & 
Kelley 1979, 1977).
I he native molecular weight of the purified enzyme 
was calculated to be 38 200 based on measurements of the
O
Stokes radius of 24A and the sedimentation coefficient, 
•’’20 w 3.8x10 1' . The subunit molecular weight from 
SDS gel electrophoresis was estimated at 41 000 which 
suggests that human erythrocyte ADA is a single polypep­
tide chain. Staining with Schiff reagent suggested that 
the polypeptide chain is glycosylated (Dadonna & Kelley 
1979, 1 976; Schrader efc a I 1976).
1.7.2. Isozymes of adenosine deaminase (Figs 12 & 13)
A method for the detection of isozymes of ADA in 
human red- :el1 naemolysates was first described by 
Spencer et a! (1968). Three different types of isozyme 
pattern were observed. These patterns were found to be 
genetically inherited and occurred at polymorphic fre­
quencies in population samples representing English,
Negro and Indian peoples.
Each pattern consisted of at least three isozymes. 
In the type designated ADA-1 there were three regularly 
spaced components which exhibited decreasing staining 
intensity in order of their anodal electrophoretic
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mobilities. The type ADA-2 pattern also consisted of 
three isozymes but differed from the ADA-1 pattern in 
being appreciably slower so that the middle zone of the 
ADA-2 had the same electrophoretic mobility as the 
slowest zone of ADA-1. The pattern which exhibited 
four isozymes was designated ADA 2-1 and had the appear­
ance of a mixture of ADA-1 and ADA-2 patterns in roughly 
equal proportions.
Amongst the Negro populations of southern Africa 
the common allele ADA 1 assumes a frequency of 1. The 
presence of rare individuals who display the ADA 2-1 
phenotype is assumed to have be ^ n a result of admixture
with Caucasoid and 'Coloured' populations. The South
2
African Caucasoid population carries the ADA allele at 
a frequency comparable to that found in related pecu­
lations in Western Europe, North America and Indian 
(Jenkins & Lane 1979).
Hindu Indians acpear to have a characteristically 
high frequency of ADA2 (0.107) whereas Moslems have a 
frequency similar to that found among West Europeans 
(0.066) (Jenkins & Lane 1979).
A low frequency of ADA2 was found among the 
Afrikaaners in Windhoek. These people are the descend­
ants of a relatively small number of ancestors, therefore, 
founder effect may well be a cause (Jenkins & Lane
1979) .
An interesting effect of storage of red-cell
lysates at 4°C was no iced after several days. The 
relative staining intensities of the various isozymes 
changed progressively with time. In type ADA-1, for 
example, the slowest isozyme gradually became weaker and 
the intermediate and faster isozymes became stronger in 
staining intensity. A gradual increase in the staining 
intensity of the more anodal isozymes was also observed 
in ADA-2 and ADA 2-1 lysates, at the expense of the 
slowest components (Spencer at at 1968).
These storage effects can be minimized or reversed, 
however, by the addition of B-mercaptoethanol, a strong 
reducing agent, to the red-cell lysates at a final concen­
tration of 2V>mM. The storage effects can also be accele­
rated by the addition of oxidized glutathione to red-cell 
lysates. These findings suggest that each of the isozymes 
contains at least one reactive sulphydryl group capable 
of undergoing an exchange reaction with oxidized glu­
tathione which is known to accumulate in red cells on 
storage. The addition of a glutathione peptide to the 
isozyme molecule would increase the negative charge and 
hence its anodal electrophoretic mobility. Therefore the 
three banded isozyme of red-cell ADA arises from secondary 
modifications of a primary gene product by the addition 
of one or two more negative charges.
When tissues other than red cells were examined 
for ADA activity by starch gel electrophoresis, most
lysates at 4°C was noticed after several days. The 
relative staining intensities of the various isozymes 
changed progressively with timti. In type ADA-1, for 
example, the slowest isozyme gradually became weaker and 
the intermediate and faster isozymes became stronger in 
staining intensity. A gradual increase in the staining 
intensity of the more anodal isozymes was also observed 
in ADA-2 and ADA 2-1 lysates, at the expense of the 
slowest components (Spencer al 1968).
These storage effects can be minimized or reversed, 
however, by the addition of B-mercaptoethanol, a strong 
reducing agent, tc the red-cell lysates at a final concen­
tration of 20mM. The storage effects can also be accele­
rated by the addition of oxidized glutathione to red-cell 
lysates. These findings suggest that each of the isozymes 
contains a: least one reactive sulphydryl group capable 
of undergoing an exchange reaction with oxidized glu­
tathione which is known to accumulate in red cells on 
storage. The addition of a glutathione peptide to the 
isozyme molecule would increase the negative chsige and 
hence its anodal electrophoretic mobility. Therefore the 
three banded isozyme of red-cell ADA arises from secondary 
modifications of a primary gene product by the addition 
of one or two more negative charges.
When tissues other than red cells were examined 
for ADA activity by starch gel electrophoresis, most
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tissue isozymes were found to be similar to the red- 
ccl1 ADA isozyme but in many tissues additional isoenzyme 
forms were observed which differed in electrophoretic 
behaviour, in sulphydryl group activity and also in 
molecular size from the red-cell isozymes (Edwards et al 
1971).
This second set of ADA isozymes did not exhibit 
the polymorphism of red-cell ADA although they were 
clearly heterogeneous in that their relative intensities 
varied between tissues in a tissue-specific way (Edwards 
et al 1971).
These data were initially interpreted as evidence 
for as many as four separate loci for ADA; a red-cell 
ADA locus and three tissue-ADA loci. This multiple locus 
hypothesis was effectively disproved when a child who was 
ADA-deficient and suffering from SCID was found to lack 
not only the red-cell isozymes of ADA but also all of the 
tissue-specific isozymes. Thus it appeared that in spite 
of the tissue-to-1issue variation in electrophoretic 
mobility, the different ADA enzyme activities were con­
trolled by a single structural genetic locus (Hirschhorn 
et al 1973) . The discovery of the ADA binding protein 
(Akedo et al 1972; Nishihara 1973) and the tnterconvert- 
ability of the large and small forms of ADA (Van der 
Weyden & Kelley 1976) provided a theoretical basis for 
the tissue-spoci*jc variation of ADA. A little later it 
was discovered that most of the miltiple forms of 'tissue
ADA were glycoproteins which differed in their access­
ible sugar residues. This suggested that the binding 
protein was a single glycoprotein with heterogeneous 
carbohydrate content (Swallow et at 1977). By now the 
structural gene for ADA had been mapped to a single 
structural locus on chromosome 20 (Creagan et at 1973; 
Tischfield et al 1974) which was subsequently confirmed 
with the cloning of the structural gene for ADA (see 
later Orkin et al 1983).
In 1977, Champion and Shows reported that in 
fibroblasts from patients with mucolipidosis II (I-cexl 
disease) and mucolipidosis III certain lysosomal enzymes 
as well as ADA, which is a non-lysosomal enzyme, showed 
altered electrophoretic mobilities that were, in part, 
attributable to the presence of excess sialic acid 
residues on the enzyme molecules. A similar observation 
was made on two sibs with sialidosis type I (Swallow et 
al 1979). The catalytic subunit of ADA contains little 
or no carbohydrate, however, the binding protein is 
glycosylated. Swallow ci al (1981), after further 
electrophoretic analysis of 12 different patients with 
primary or secondary aialidase deficiency suggested that 
the increased electronegativity of a number of lysosomal 
enzymes, as well as ADA was due to the presence of 
excess sialic acid residues on the enzyme molecules and 
that sialidase played a role in the normal post-trans-
lationa 1 modification of 9 ^.ycoprotein enzymes by 
clipping off terminal sialic acid residues from the end 
of sugar chains after the completion of glycoprotein 
synthesis. The altered electrophoretic mobility of ADA 
implied that sialidase may act outside the lysosome as 
ADA is a soluble enzvme and also is over-sialylated in 
sialidase deficiency.
In summary, the red-cell, triple-banded ADA iso­
zyme pattern is a consequence of secondary modification 
of a primary gene product at the sulphydryl sites. The 
tissue-specific isozymes are generated when the primary 
ADA gene product is bound by a tissue conversion factor 
of ADA binding protein, w M c h  is itself glycosylated in 
a tissue-specific manner.
1.7.3. The minor form of ADA: ADA]
Early studies on the molecular heterogeneity of 
adenosine deaminase indicated the presence of small 
amounts of an 'intermediate' form of the enzyme, (molecu­
lar weight 110 000) in a variety of human tissues 
compared to the large and small forms with molecular 
weights of 298 000 and 38 000 respectively (Van der 
Weyden 1976). Analysis of splenic tissue from a patient 
with ADA deficiency and SCID, revealed in addition, that 
.he molecular form of ADA pr sent was exclusively the 
•intermediate species' (Van der Weyden al 1974). It 
was subsequently demonstrated by Schrader at at (1978)
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that an 'aminohydrolagc' intermediate in molecular 
weight between large- and small-form ADA existed in 
normal spleen as we 11 as in splenic tissue of another 
patient with ADA deficiency and immune dysfunction.
This splenic 1 ami nohydrolase' appeared to be different 
from normal ADA based on Km value, immunoreactivity, 
pH optimum and insensitivity to the potent ADA inhibitor 
EHNA (Schrader et at 1978). Subsequently, it was 
demonstrated that an aminohydrolase was present in six 
normal and five ADA-deficient cell lines waich appeared 
to be similar to the previously described splenic amino­
hydrolase. Analysis of the enzymatic, ohysical and 
immunoreactive properties of the lymphoblast aminohydro­
lase suggested that this enzyme was distinct from and 
unrelated to ADA (Dadonna & Kelley 1981) (see Table 1).
The minor form of ADA, sometimes referred to as 
A D A , (Hirschhorn et al 1979) differs from the major ADA 
in that it is active only at high substrate concentrations 
and is non-EHNA-inhibitible. Residual ADA activity 
found at high substrate concentrations in cells from ADA- 
deficient oatients could represent in whole, or in part, 
this additional ADA2 activity. Therefore, when investi­
gating ADA from suspected ADA-deficient patients the 
enzyme should be assayed at low substrate concentration 
and only the E H N A - i n h i b i t i b l e  ADA activity measured by 
performing assays in duplicate, with and without the
inhibitor.

8. PARTIAL ADA DEFICJENCY
1.8.1. Discovery in the !Kvrny
Inherited deficiency of ADA usually results in, 
and appears to be causally associated with the condition 
of severe combined immunodeficiency disease (SCID) which 
is characterised by a lymphopoenia and lack of both 
cellular and humoral immunity. This usually proves 
fatal within three years unless treated by bone marrow 
transplantation. Shortly aftnr the initial description 
of ADA-deficient SCID, an apparently healthy 10-year old 
IKung child was described who lacked ADA in his erythro­
cytes (Jenkins 1973). His ADA deficiency had been dis­
covered by starch gel electrophoresis whilst screening 
IKung blood samples for a range of genetic markers 
including ADA. E l e c t rophoresed haemolysates from this 
child were found to lack ADA activity whereas his father 
and mother demonstrated the ADA-1 isozyme pattern but 
with reduced intensity. His immunoglobulin levels were 
normal although there was evidence of a slight impairment 
of his cellular immunity. Absence of lymphopoenia was 
demonstrated with T and B cells in normal proportions.
The haemoglobin and red cell counts were also normal. 
Adenosine deaminase activity was assayed and the 
propositus was found to have 2-3. of normal activity In 
his red cells, 10-15. of normal in his white cells and 
33% of normal In cultured fibroblasts, starch gel 
electrophoresis of ADA from fibroblast extracts showed
the ADA-2 isozyme pattern although, of weak intensity 
along with the normal pattern of ADA 'tissue' isozyme.
These data were interpreted as showing that the 
boy was homozygous for a rare ADA allele which was 
different from that involved in SCID, and that the level 
of ADA activity in the various tissues including lympho­
cytes was sufficient for normal immune function. Studies 
on the heat stability of white cell ADA showed that at 
56°C the residual enzyme had a half life of 5 minutes 
compared with a control value of about 50 minutes. There­
fore this rare ADA allele appeared to be responsible for 
an unstable form of the enzyme resulting in deficiency 
in the anucleated, mature red cells but with sufficient 
residual activity in the lymphoid cells to preserve 
immune function.
Population studies on the IKung revealed that 
the gene coding for this unstable enzyme was present at
g
polymorphic frequencies. This allele was designated ADA , 
and its frequency in the IKung was 0.014, while ADA had 
a frequency of 0. 896, and ADA2 was not encountered at 
all. A total of three homozygous IKung Individuals from
2 families were found (Jenkins 1973) Jenkins at 1976,1979). 
Subsequently, four additional children from three families 
belonging to other populations have been found to have 
'partial' ADA deficiency (Hlrschhorn et '■' 1979).
rhnse individuals had several features in common. 
All were deficient for ADA in their red cells but had 
substantial residual ADA activity in their peripheral 
blood mononuclear cells. They showed only slight, if 
any, accumulation of the toxic metabolite deoxy-ATP in 
their erythrocytes and excreted barely detectable amounts 
of deoxyadenosine in urine. This contrasts with the 
500- 1 000-fold elevation in erythrocyte deoxy-ATP content 
and urinary deoxyadenosine excretion by ADA-dcficient 
SC1D patients. Thus, total body adenosine deaminating 
activity was sufficient in these partially ADA-deficient 
children to prevent iccumulatlon of deleterious nucleo­
side and nucleotide compounds (Hirschhorn , t i! 1963).
There are several different mechanisms which could 
result in genetic absence of ADA in erythrocytes but 
presence in lymphoid cells. One of these is the existence 
of two different Al A isozymes controlled by two separate 
loci in the two types of cells. This theory appears to 
be extremely unlikely since a single locus tor ADA has 
been mapped to chromosome 20 and SC ID patients show a 
profound lack of ADA activity in all tissues.
A second theory is that a mutation is involved 
at a r e y  latcry locus controlling expression of ADA in 
e r y t h r o c y t e s .  At the moment there is only slight sup-
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portive evidence for the regulatory locus theory. For 
example, Valentino has reported autosomal, dominant 
inheritance of a 50-fold increase in ADA activity of 
erythrocytes but normal activity in lymphocytes and 
fibroblasts (Valentine et at 1977). Sioiliano et al 
(1978) have reported expression of human ADA in hybrids 
between a human tumour line not expressing ADA and a 
murine cell line, suggesting a regulatory locus. Finally, 
a mutation at a structural locus coding for an unstable 
enzyme could result in absent or markedly diminished 
activity in erythrocytes because they are incapable of 
synthesizing new protein and have a relatively long life 
span during which time an unstable enzyme could be 
expected to diminish markedly in activity.
1.8.3. Genetic heterogeneity
Adenosine deaminase from four lymphoid cell lines 
derived from partially ADA-defIclent Individuals has 
been Intensively studied and despite the common features 
described above there appears to be a high degree of 
heterogeneity In partial ADA deficiency to the degree 
that four different structural mutations appear to be 
involved (Hlrschhorn «t al 1983, Dadonna al 1984).
One child had an enzyme which was unstable at 56"C 
had a more basic than noi~al Isoelectric point and a rate 
of enzyme degradation »<»o <B lymphoblast cell lines) 
which was one- and a-half times greater than normal. A
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second child had an enzyme with normal heat stability, 
a moro acidic isoelectric point, .in increased rate of 
degradation of ADA in vivo and a reduced rate of 
enzyme synthesis, although mRNA levels were normal.
The third child (the IKung boy) had an enzyme with a 
normal isoelectric point but diminished stability at 
56°C. The latter cell, line was the only one of the four 
to show a two-fold elevation of ADA mRNA. Protein turn­
over studies demonstrated that ADA from the child was 
degraded at twice the normal rate suggesting a mutation 
in the protein which renders it more susceptible to 
proteolysis in vivo. The rate of synthesis, in addition 
was almost one- and a-half times as fast as normal.
The fourth child had an enzyme with a normal isoelectric 
point and normal heat suability at 56°C which was 
initially taken as evidence for a mutation at the oostu- 
lated regulatory locus. Procoin turnover studies, how­
ever, showed a slower rate of synthesis and a rate of 
degradation approximately twice the normal rate, despite 
having normal mRNA levels. This additional evidence is 
more suggestive of a structural mutation than any 
regulatory fault (Hlrschhorn el al 19113; Dadonna e. at
1984).
.9. RECENT DEVELOPMENTS
1.9.1. The ADA gong
Several groups have isolated sequences encoding
human ADA (Valerio c t -i I 1983; Orkin r i / 1 983; 
Wlqinton rt at 1983). The availability of these clones 
has allowed studies of the structure and exnression of 
the ADA qene in wild-type and ADA-deficient cell lines 
(Valerio #-1 a! 1984a; Dadonna 1 at 1984; Adrian <?t al 
1984) .
Northern blot analysis revealed a major ADA mRNA 
species of about 1.5 kilobases that has been shown to 
code for the ADA protein (Valerio et al 1983). Sequence 
analysis of a cDNA clone for human ADA revealed an open 
reading frame with the capacity to code for a protein 
with a molecular weight of 40 762 (Valerio rt al 1984b). 
The complete gene was subsequently isolated and found to 
consist of 32kb of genomic DNA containing 12 exons.
The promoter region of ADA is unusual in that 
it does not appear to have tic classical TATA box, which 
is typically locat I 20-30 bases 5' to the start of the 
coding sequence and has the consensus sequence TATA^A* 
(lireathnach & Cham bon 1981). The so-called CAAT box 
which is often found 8Obp 5 1 to the start of the first 
exon of eukaryotic genes (Uenoist rt a 19 80) is also 
absent. The promoter region is, however, i ich in (->/C 
content, a feature of some other gene promoter regions
(Valerio et a I 1985).
1.9.2. Molecular basis o
The molecular basis of ADA deficiency has also
been investigated using ADA cDNA clones. In most ADA- 
deficient cell 1 it.es, ADA mRNA is present in normal or 
supranormal amounts (Dadonna <? t al 1984; Valerio et al 
198 4; Dadonna et  a l 1985) but enzyme activity and 
immunologically detectable protein levels are greatly 
diminished (Dadonna et  al 1980; Wiginton & Hutton 1982). 
The majority of the mutations are therefore thought to 
lie within the protein coding sequence. Because the ADA 
mRNA in ADA-deficient cell lines can often be translated 
in v i t r o into normal sized ADA protein (Valerio et  al 
1984; Adrian et  al 1983), it can be inferred that the 
mutant ADA proteins are sometimes unstable i n vivo. SI 
nuclease digests single-stranded RNA and DNA. Hybridi­
zation between complimentary strands of DNA or DNA and 
RNA protects the molecules from this enzyme. If the 
hybridization is incomplete, the region of imperfect 
pairing will also be digested which will be revealed by 
subsequent strand separation by denaturation and electro­
phoresis. Si niclease analysis of mRNA from se en ADA- 
deficient cell lines revealed four with patterns indis­
tinguishable from those of normal cells and three with 
structural aberrations In the mRNA (Adrian «t al 1984). 
These results suggested that point mutations are primarily 
responsible for most, though not all cases of ADA defici­
ency. in one particular cell lino, GM-1715, derived 
from a patient with ADA deficiency and immunodeficiency, 
sequence analysis of the cloned ADA DNA revealed a point
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mutation at base number 302, codon 101, which predicts 
a glutamine residue to be substituted for arginine in 
the ADA protein (Bonthron et al 1985), which appeared 
to be solely responsible for the loss of function of 
this allele. Restriction fragment length analysis, 
however, suggested that this cell line was heterozygous 
for two different ADA deficiency allelds (Bonthron et 
al 1985) . It can be confidently predicted that in the 
near future, further sequence analysis of other mutant 
alleles will permit the detailed mapping of sites in 
the ADA protein that are critical to enzyme function 
and stability.
MATERIALS AND MHTHODS
2.1. Subjects
Ihe proband, an apparently healthy Bantu-speaking 
blacl> male in his early thirties, was discovered during 
i o v  tine ADA phenotyping by starch gel electrophoresis.
He and hts family lived in the Kastern Cape around Port
1.1 ifabeth. All of them, including the proband, his 
parents, two sisters, wife and child, consented to give 
blocd which was collected at the South African Institute 
for Medical Research, Port Elizabeth laboratories.
These samples were '.hen flown to Johannesburg on the 
first available flight. Subsequently ACD blood samples 
from 63 random Xhoia biood donors were also M o w n  to our 
laboratory from Port Elizabeth for a population study
the incidence of partial ADA deficiency.
2.1.1 Sample preparation
The venous blood samples collected into acid- 
citrate-dextrose (ACD) anticoagulant 'Vac-U-Tesf tubes 
were received in the laboratory in good condition within 
twenty-four hours of collection. Plasma was temoved 
and the red cells washed three times in 0.9% baline with 
removal of the white cell buffy coat aft<*r each centri­
fugation. The red cells were preserved by the addition 
of an equal volume of a glycine based preserving fluid 
(Trlpotasslum cllrate (KjC j H ^ . ^ O )  0.06 moles/t, sodium
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dlhydroqon phosphate (NaH2P04 .2H20) 0.02 moles// dis- 
solvod in GOOmfs of deionined vMtrr and 400mfs ylyccrol), 
and stoi od at -20 C . When a sample was required the 
preserving fluid was removed by overnight dialysis 
against 0.9% saline at 4°C. Tie red cells were then 
washed in 0.9% saline and haemolysed by freezing and 
thawing or by sonication. Alternatively, haemolysates 
were prepared from undialysed, preserved red cells by 
sonication and from washed, fresh red <;ells by freezing 
and thawing or by sonication.
2.2. PREPARATION OF WHITE CELL LYSATES
Two volumes of 3 percent w/v Dextran in 0.9 per­
cent w/v saline were added to a measured volume of whole 
blood in a measuring cylinder, inverted to ensure thorough 
mixing and then allowed to stand at room temperature for 
30 minutes. Most red cells settled down allowing the 
supernatant to be removed. This was centrifuged at 600g 
for five minutes to spin down the white cells and any 
remaining red cells. The supernatant was then discarded 
and the cell pellet cooled on ice. Ihe remaining red 
cells were lysed by adding 3nit of chilled water and mixed 
for 70 seconds wi th a 5mf automatic-ad just ah 1 e-pipetto. 
This solution was then mixed well with Imf of U 6  percent
w/v sodium chloride and centrifuged at 600g for five 
minutes. The supernatant containing haemoglobin and 
lysed red cell ghosts was discarded. This procedure
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for lysing red cells was repeated if necessary until 
the cell pellet consisted of white cells only. This 
pellet was washed twice with 4m£ of cold 0.9 percent w/v 
sodium chloride ard finally stored frozen in the pellet 
form at -70°C.
2.3. HAEMOGLOBIN AND PROTEIN ESTIMATION IN LYSATES
Haemoglobin concentration was measured by adding 
20ul of haemolysate diluted 1:5 with water to 3m£ of 
ferricyanide-cyanide reagent (Drabkins solution). The 
pigment is converted to cyanmethaemoglobin and the 
optical density read at 540nm after fifteen minutes 
incubation at room temperature (Beutler 1975). The 
Drabkins solution was made by dissolving 200mg K^Fe(CN)^, 
50mg KCN and 1g NaHCO^ in U  distilled water. The 
spectrophotometer was calibrated for haemoglobin esti­
mation and found to give an optical density reading of 
0.248 when the haemoglobin concentration was known to be
Img Hb per Drabkins.
Protein estimations in white cell lysates were 
made by the method of Lowry (1951). A series of
protein standards was prepared by dissolving known amounts 
of bovine serum albumin (Sigma) in distilled water in the 
range 30ug/mf to ISOug/mt. One millilitre of a 2 percent 
w/v potassium sodium tartrate solution was added to 1mt 
of 1 percent w/v copper sulphate and 98mfs of a solution 
which consisted of 2 percent w/v „a,CO, and 0.1M NaOH,
and well mixed. Four millilitres of this resulting 
solution were added to a series of tubes which contained 
either linf ol the protein standard or Imt of the white 
cell lysate diluted 1:50. Four millilitres of the same 
solution were added to 1m( of water to provide the 
'blank'. All tubes were prepared in duplicate and then 
allowed to stand at room temperature for ten minutes. 
During this time a working solution of Folin-Ciocalteu 
reagent (Merck) was prepared by diluting it in the ratio 
of Imf Folin's reagent to 1 .36mf of water. At the 
appropriate time 0.5mf of the diluted Folin's reagent 
was added to each tube and given an instant, vigorous 
mixing. The mixtures were then allowed to stand at room 
temperature for a further thirty minutes after which the 
optical density at a wavelength of 660nm of each solution 
was measured on a Perk in-Elmer 550 spectrophotometer.
The known protein standards were used to plot a standard 
curve from which the protein levels in the test samples 
were determined.
2.4. STARCH GEL ELECTROPHORESIS OF ADA
The bridge buffer for electrophoresis contained 
citric acid monohydrate, 0.4 1M and sodium hydroxide 
1.21M and had a pH of 6.5. The gel buffer consisted 
of 0.005M L-histidi no monohydrochloride, which had been 
adjusted with a dilute solo Lon of NaOH to pH 6.5. Ten 
percent starch gels were p> pared and samples were applied
on Whatman No 17 filter paper rectangles which had been 
saturated with the lysates. Flectrophoresis w-?s carried 
out horizontally for 16 to 17 hours at ♦4°C with an 
applied potential difference of 3.5 V/cm constant voltage. 
The gels were then sliced and the cut surfaces stained 
for adenosine deaminase using an agar overlay technique. 
The staining mixture contained 1BOmg sodium arsenate,
40mg adenosine, 6m( nitro blue tetrazolium salt solution 
(1OOmg NBT/10ml water), 2m? phenazine methosulphate 
solution (10Omg PMS/20mf H ,0), 40y1 of a suspension of 
xanthine oxidase in an ammonium sulphate solution (Boeh- 
ringer) equivalent to about 0.8 units and 40ul of a sus­
pension of nucleoside phosphorylase (Boehringer) also 
equivalent to about 0.8 units, dissolved in 20ml Tris 
HCf buffer, 0,05M pH 8. One gramme of agar (Difco P-acto- 
agar) was dissolved by boiling in about 10ml wator and 
added to the staining mixture. Incubation was carried 
out at 37°C for about two hours.
The reaction proceeds as shown in Fig 14.
ADA NP
Adenosine *-*■*■ I nosine »-» Hypoxanthine xan i ne
Figure M  rormazan-NBT
The underlined components are contained In the reaction 
mixture applied to the gel. NP, nucleoside phoaphory- 
lase; XOD, xanthine oxidase, PMS, phena.lne ^ t h o s u l -  
phate, NBT. nltroblue tetrazollum. ADA, adenosine
deaminase.
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The inosine produced at the sites of adenosine 
deaminase activity is converted to hypoxanthine in the 
presence of nucleoside phosphorylase. The hypoxanthine 
is then oxidized by the action of xanthine oxidase and 
during this reaction the tetrazolium salt NBT is reduced 
in the presence of phenazine methosulphate to blue 
insoluble formazan.
2.5. ADENOSINE DEAMINASE ACTIVITY MEASUREME?”"
2.5.1. Spectrophotometrie method 
This method used to measure adenosine deaminase 
activity is very similar to that described by Hopkinson 
et al (1969). Haemolysates and white cell lysates were 
prepared as described above and the adenosine deaminase 
measured gpectrophotometrlcaUy with adenosine or deoxy- 
adenosine as substrate at pH 7.5. The red cell lysates 
were diluted 1:5 with water and 50uZ of this dilute 
haemolysate was added to l.Omf phosphate buffer, 0.05M, 
pH 7.5 containing 0 .3 0 6umoles substrate (adenosine or 
deoxyadenoslne) O.lumoles EDTA, 3umoles :,-mercapto- 
ethanol and 0.2 units of xanthine oxidase (Boehringer) 
in a final volume of 3.06mt and the rate of Increase in 
optical density at 293nm was measured in a Perkin-Elmer 
550 spectrophotometer. The reaction was carried out 
at 37-C and the blank cuvette was identical to the test 
cuvette except that adenosine was omitted. Inosine, the 
product of adenosine deaminase activity, is converted by 
nucleoside phosphorylase present in red cell lysates to 
hypoxanthine, the latter is then converted to xanthine
*>6.
and uric acid by the action of the added xanthine oxi­
dase. Thus in the presence of cxccts nucleoside 
phosphorylase and xanthine oxidase the rate of the 
increase in optical density at 293nm resulting from the 
conversion of adenosine to uric acid gives a measure of 
adenosine deaminase activity.
White (o lysate adenosine deamj ase activity 
was measured in essentially the same way as for haemoly- 
sates. White cell lysates were prepared as described 
under the methods for samule preparation and 
used without diluting. The reaction mixture in the test 
cuvette was the same as that for red cell measurements 
except for the addition of 0.2U of nucleoside phosphory­
lase. This is necessary because the_e is insufficient 
endogenous nucleoside phosphorylase present in white 
cell lysates for the reaction to proceed optimally.
Blanks were constituted in the same way as the reaction 
mixture except that 'iOuf water was added instead of white 
cell lysate.
Activity measurements were expressed in terms of 
haemoglobin concentrations for red cell lysates and 
protein concentrations for white cell lysates.
2.3.2. < m  1 m e thod
Tills method of measuring adenosine deaminase 
activity was used in addition to the spectrophotometric 
method because of its greater sensitivity, especially for
67.
meaBUFtnq the low atlenoBlnu deaminase levels found in 
thu ri'U col la of part ially defioiont sulijecf s.
The method used was the same as tltat described 
by Hirschhorn et a! (19 79), which was based on a similar 
method described by Coleman and Hutton (1975). The 
principle of this radiometric assay lies in measuring 
the conversion of (14C) adenosine to (14C) inosine; 
these two substrates being separated by descending paper 
chromatography prior to their quantitation.
rted cell lysates were prepared as described for 
starch gel electrophoresis. The haemolysates from 
individuals known to have normal adenosine deaminase 
activity wore diluted fourty-one times with ImM Tris, 
pH 7.5, whereas haemolysates from individuals known to 
be partially deficient for adenosine deaminase were 
diluted sixteen times with the same Tris buffer.
The red cell lysates were incubated with water, 
(U14C) adenosine (Amersham 500-600mCi/mmol) or deoxy- 
adenosine (Amersham >459mCi/mmol) and a 'Iris EDTA buffet, 
pH 7.5 such that the final concentrations of each com­
ponent in the reaction mixture was as follows;
(14C) adenosine or deoxyadenostne, 0.09mM, luCi/nmol 
Tris, 24m M ; EUTA, 2.4mM, EHNA, 4(H,M in a final volume 
of 1 0 0 ) , The amount of water and lysate added could be 
varied so that between 10 and JO percent of the adenosine 
was converted to Inosine during the incubation period.
68.
The incubation was carried out at 37‘ c for thirty minutes 
and the reaction terminated by the addition of 20ut of 
2.1M perchloric acid to the reaction mixture. After a 
brief centrifugation in a bench centrifuge and subse- 
guent neutralisation of a 60„t aliquot of the supernatant 
with 10uZ of 2.21M NaOH, 20„t aliquots were co-chromato- 
graphed with 3mM internal standards on DE81 paper, with
1 niM ammonium for mat e as solvent, by descending paper 
chromatography. The areas containing purines were revealed 
under UV light by their defluorescence, ;ut and the radio­
activity of these sections determined. Adenosine and 
deoxyadenosine were widely separated from hypoxanthine, 
inosine and deoxyinosine. Activities were calculated by 
determining the percentage of the total counts converted 
from substrate to product, knowing the initial substrate 
concentration and period of inactination.
2.6. M ICHAKLIS CONSTANTS
Method
The adenosine deaminase activities of samples from 
the subject and controls were measured by the radio­
chemical method, as previously described, at final sub­
strate concentrations of 5(HiM, 75pM, IOOiiM, 125iiM, 150uM 
and 175gM. The method of least squares was used to draw 
Lineweaver-Burke plots representing the data and Michael is 
constant estimates obtained from these by calculating 
reciprocals of the x-axis intercepts.
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